Advertisement

Topics

Myriad Genetics Signs Definitive Agreement to Acquire Counsyl

11:34 EDT 29 May 2018 | Investing News Network

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasive prenatal screening for $375 million through a combination of cash and Myriad common stock. Counsyl has experienced rapid growth since being founded in 2007, and … Continued

The post Myriad Genetics Signs Definitive Agreement to Acquire Counsyl appeared first on Investing News Network.

Original Article: Myriad Genetics Signs Definitive Agreement to Acquire Counsyl

NEXT ARTICLE

More From BioPortfolio on "Myriad Genetics Signs Definitive Agreement to Acquire Counsyl"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...